Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis

This systematic review and network meta-analysis evaluated the efficacy and safety of biologic therapies for moderate to severe pediatric plaque psoriasis. The analysis included randomized controlled trials with a total of 1,016 pediatric psoriasis patients, though the specific study settings were not reported. The follow-up period for efficacy outcomes ranged from 12 to 16 weeks, while safety outcomes were assessed over 12 to 20 weeks. The analysis compared multiple biologic therapies against placebo, though the exact dosing protocols for each agent were not detailed in the available data.

The interventions examined included ixekizumab, secukinumab high dose, and standard-dose ustekinumab, all compared against placebo. While the primary outcome was not explicitly stated, the analysis focused on several key secondary outcomes: PASI75, PASI90, PASI100, and CDLQI score of 0/1 (CDLQI 0/1). These represent standard measures of psoriasis severity and quality of life in pediatric patients.

For efficacy outcomes, all biologic therapies exhibited significantly higher response rates compared to placebo for both PASI75 and PASI90, though specific effect sizes, absolute numbers, p-values, and confidence intervals were not reported. Regarding specific agent performance, ixekizumab ranked highest for PASI100 response with a surface under the cumulative ranking curve (SUCRA) value of 0.9 and a mean rank of 1.8. For PASI90 response, secukinumab high dose ranked best with a SUCRA of 0.8 and mean rank of 3.0. Standard-dose ustekinumab exhibited superior performance for CDLQI 0/1 with a SUCRA of 0.8 and mean rank of 2.2, and also performed well for PASI75 with a SUCRA of 0.9 and mean rank of 2.2.

Safety and tolerability findings were notably limited in this analysis. The data did not report adverse event rates, serious adverse event rates, discontinuation rates, or specific tolerability concerns for any of the biologic therapies examined. This represents a significant gap in the evidence base for these treatments in pediatric populations.

When considering these results in the context of prior research, this network meta-analysis provides comparative efficacy data that was previously limited for pediatric psoriasis. The finding that all biologics were significantly superior to placebo aligns with established evidence from adult studies and smaller pediatric trials. However, the lack of significant differences between individual biologic therapies contrasts with some adult data suggesting differential efficacy profiles.

Methodological limitations of this analysis include the acknowledged need for better-powered trials in pediatric populations, which affects the certainty of comparative conclusions. The network meta-analysis approach relies on indirect comparisons between studies that may have differing designs, populations, or outcome measures. Additionally, the absence of detailed safety data and specific effect sizes limits the clinical applicability of the findings.

For clinical practice, these results confirm that biologic therapies demonstrate efficacy superior to placebo for pediatric plaque psoriasis across multiple outcome measures. However, the absence of significant differences between individual biologics suggests that treatment selection may depend on factors beyond short-term efficacy, including safety profiles, administration frequency, patient preference, and cost. The analysis highlights that standard-dose ustekinumab performed well on both clinical (PASI75) and quality of life (CDLQI 0/1) measures, while ixekizumab showed particular strength for complete clearance (PASI100).

Important questions remain unanswered, particularly regarding long-term efficacy and safety beyond 20 weeks, comparative safety profiles between agents, optimal dosing strategies in pediatric populations, and effects on growth and development. The analysis specifically notes the need for better-powered trials to establish clearer differences between individual biologic therapies and to provide more robust safety data for informed clinical decision-making.